TMEM252

Across TCGA pan-cancer cohorts, TMEM252 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM252 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM252 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM252 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, BLCA, and SKCM are the cancer types where TMEM252 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BLCA	OS	Median	All	0.212	0.720	.007	12	view →
SKCM	OS	Median	III,IV	0.072	0.814	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.625	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM252–LIHC (DFS)

Open the LIHC breakdown →